| abstract |
The present invention relates to a cell reprogramming inducing composition. The indazole derivative compounds contained in the composition of the present invention exhibit an improved biological profile and can perform efficient cell re-programming. In addition, the indazole derivative compound of the present invention does not show cytotoxicity unlike the conventional low molecular weight cell reprogramming inducing compounds (for example, ribosin or BIO), and thus high growth in the cell therapeutic agent market can be expected in a clinical application. In contrast, conventional indazole derivatives are not known to be used for cell reprogramming, and the compounds of the present invention have cytotoxicity or significantly lower cytotoxicity compared to conventional indazole derivative compounds, The programming capability is very good. |